tiprankstipranks
Advertisement
Advertisement

RVMD Stock Latest News

Revolution Medicines assumed with a Buy at Truist
The FlyRevolution Medicines assumed with a Buy at Truist
3d ago
RVMD
Revolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Raising Long-Term Upside Potential
PremiumCompany Announcements
Revolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Raising Long-Term Upside Potential
6d ago
RVMD
Adlai Nortye initiated with a Buy at JonesResearch
PremiumThe Fly
Adlai Nortye initiated with a Buy at JonesResearch
6d ago
ANL
ERAS
Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry
PremiumCompany Announcements
Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry
13d ago
RVMD
Revolution Medicines Signals Breakout With RAS Wins
PremiumCompany Announcements
Revolution Medicines Signals Breakout With RAS Wins
13d ago
RVMD
Revolution Medicines price target raised to $185 from $170 at BofA
PremiumThe FlyRevolution Medicines price target raised to $185 from $170 at BofA
13d ago
RVMD
Revolution Medicines price target raised to $172 from $120 at Piper Sandler
Premium
The Fly
Revolution Medicines price target raised to $172 from $120 at Piper Sandler
13d ago
RVMD
Revolution Medicines: Buy Rating Backed by Strong Daraxon Launch Signals and Pancreatic Cancer Upside Optionality
Premium
Ratings
Revolution Medicines: Buy Rating Backed by Strong Daraxon Launch Signals and Pancreatic Cancer Upside Optionality
13d ago
RVMD
Revolution Medicines price target raised to $205 from $175 at Guggenheim
PremiumThe Fly
Revolution Medicines price target raised to $205 from $175 at Guggenheim
14d ago
RVMD
Ami Fadia Reiterates Buy on Revolution Medicines, Slightly Lowers Price Target to $183 Amid Higher Non‑Cash Expenses and Expanded RASolute 301 Trial
PremiumRatings
Ami Fadia Reiterates Buy on Revolution Medicines, Slightly Lowers Price Target to $183 Amid Higher Non‑Cash Expenses and Expanded RASolute 301 Trial
14d ago
RVMD
Revolution Medicines reports Q1 EPS ($2.29), consensus ($1.84)
PremiumThe Fly
Revolution Medicines reports Q1 EPS ($2.29), consensus ($1.84)
14d ago
RVMD
Revolution Medicines sees FY26 operating expenses of $1.7B-$1.8B
PremiumThe Fly
Revolution Medicines sees FY26 operating expenses of $1.7B-$1.8B
14d ago
RVMD
Revolution Medicines announces NEJM publication of data on Daraxonrasib
PremiumThe FlyRevolution Medicines announces NEJM publication of data on Daraxonrasib
14d ago
RVMD
Revolution Medicines: Buy Rating Reiterated as Pipeline Advances, Trial Upsized, and $263 Price Target Maintained
Premium
Ratings
Revolution Medicines: Buy Rating Reiterated as Pipeline Advances, Trial Upsized, and $263 Price Target Maintained
14d ago
RVMD
FDA permits expanded access for Revolution pancreatic cancer drug
Premium
The Fly
FDA permits expanded access for Revolution pancreatic cancer drug
19d ago
RVMD
Erasca price target raised to $9 from $2 at BofA
PremiumThe Fly
Erasca price target raised to $9 from $2 at BofA
23d ago
ERAS
RVMD
Erasca believes Revolution infringement claims ‘without merit,’ says Stifel
PremiumThe Fly
Erasca believes Revolution infringement claims ‘without merit,’ says Stifel
23d ago
ERAS
RVMD
Erasca sinks after Revolution Medicines alleges patent infringement
PremiumThe Fly
Erasca sinks after Revolution Medicines alleges patent infringement
23d ago
ERAS
RVMD
Revolution Medicines: Daraxonrasib Data De‑Risk Pivotal Pancreatic Cancer Program, Supporting Buy Rating and $169 Target
PremiumRatings
Revolution Medicines: Daraxonrasib Data De‑Risk Pivotal Pancreatic Cancer Program, Supporting Buy Rating and $169 Target
29d ago
RVMD
Buy Rating on RVMD Driven by Promising Pancreatic Cancer Data and Next‑Generation RAS Franchise Potential
PremiumRatingsBuy Rating on RVMD Driven by Promising Pancreatic Cancer Data and Next‑Generation RAS Franchise Potential
29d ago
RVMD
Revolution Medicines: Strong Zoldonrasib Efficacy and Strengthened Balance Sheet Support Buy Rating and Higher Target
Premium
Ratings
Revolution Medicines: Strong Zoldonrasib Efficacy and Strengthened Balance Sheet Support Buy Rating and Higher Target
1M ago
RVMD
Revolution Medicines to present updated Phase 1 data for zoldonrasib
Premium
The Fly
Revolution Medicines to present updated Phase 1 data for zoldonrasib
1M ago
RVMD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >